openPR Logo
Press release

Rigel and Proteros renew X-ray protein crystallography collaboration

07-12-2011 10:42 AM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried, Germany, July 12, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that it has renewed its agreement with Rigel Pharmaceuticals, Inc. (Rigel) to provide structural biology services for a Rigel drug discovery program.

Under this agreement, Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts. Proteros will deploy its high throughput crystallography platform and proprietary technologies.

Proteros focuses on providing structure based drug discovery services and continues to invest in developing its service platform which consists of X-ray protein crystallography, kinetic and thermodynamic compound profiling and integrated lead discovery based on a novel compound and fragment library of over 30,000 novel target directed molecules.

Cony D’Cruz, CBO and President of Proteros (US) Inc. said: “This agreement continues the long-standing structural biology collaboration between the two companies. We are pleased to be supporting Rigel with its pioneering research efforts.”

About Rigel Pharmaceuticals, Inc.:
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets
that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor in phase 3 clinical trials for rheumatoid arthritis (w/AstraZeneca), and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

About Proteros biostructures GmbH:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

Proteros biostructures GmbH
Dr. Thomas Waldmann
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 - 0
Fax: +49 (0) 89 7007 61 - 15
Email: business@proteros.com
Website: www.proteros.com

Rigel Pharmaceuticals, Inc.
Mr. Raul R. Rodriguez
President and Chief Operating Officer
1180 Veterans Blvd.
South San Francisco, CA 94080, USA
Phone: + 1 650 624 1100
Fax: + 1 650 624 1101
Email: invrel@rigel.com
Website: www.rigel.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rigel and Proteros renew X-ray protein crystallography collaboration here

News-ID: 183118 • Views: 2638

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Rigel

Rheumatology Therapeutics Market 2020 - AstraZeneca, Rigel pharma, Abbott Labora …
CMI analyses the Rheumatology Therapeutics trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to produce detailed market segmentation, and this is what you will find here: a report without any unnecessary padding, giving a unique analysis of the sector. Major Companies Covered in this report:- 1 AstraZeneca. 2 Rigel pharma. 3 Abbott Laboratories. 4 Pfizer. 5 Amgen. 6 Janssen Biotech. 7 Merck Co. Inc. Request a Sample Copy of the
Chronic immune thrombocytopenia treatment Market Growth, Share, Demand, Innovati …
The chronic immune thrombocytopenia treatment is the most important treatment for those patient which are suffering from bleeding problem, the blood clotting process get slow or did not occurs in patient due to which major health issue can affect the body. The process of blood clotting is controlled by platelets or thrombocytes, the deficiency of platelets or thrombocytes in blood affect the patient during surgery or any major or
Vital Signs Simulators Market Key Player Global Analysis - RIGEL Medical, Simula …
The Vital Signs Simulators Report consists of all the basic information regarding the Vital Signs Simulators market. The all-inclusive report will aid users to understand the market current trends, industry growth drivers, share, analysis, size, production, forecast trends, supply, sales, demands, and many other aspects. The analysis was accomplished using an objective amalgamation of primary and secondary data including contributions from major participants in the market. The global Vital Signs
Nov 20, 2017: Electrosurgical Analyzer Market Forecast 2023 Rigel Medical, Medtr …
A market study ” Global Electrosurgical Analyzer Market ” examines the performance of the Electrosurgical Analyzer market Size 2017. It encloses an in-depth Research of the Electrosurgical Analyzer market state and the competitive landscape globally. This report analyzes the potential of Electrosurgical Analyzer market in the present and the future prospects from various angles in detail. Get Free Sample Of Report: https://goo.gl/JZKzRF The Global Electrosurgical Analyzer Market 2017 report includes Electrosurgical Analyzer
Global Electrosurgical Analyzer Market 2017 - Fluke Biomedical, Rigel Medical, B …
Electrosurgical Analyze Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors. Scope of the Report: This report focuses on the Electrosurgical Analyze in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Sample of Report
Global ECG Simulator Market Research Report 2017 Top Industry Players : Symbio C …
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of ECG Simulator in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Global ECG Simulator market competition by top manufacturers, with production, price, revenue (value)and market share for each manufacturer; the top players including Symbio Corporation GOSSEN METRAWATT Datrend Systems Inc Fluke Biomedical TRISMED HE Instruments Labtech Laerdal Medical Simulaids Medigate Pronk Technologies RIGEL Medical On the basis of product, this report